Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir Syrup in Pediatric Solid Organ Transplant Recipients
NCT00090766Phase 3Completed
- Sponsor
- Roche
- Start
- May 2004
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label trial of valganciclovir in cytomegalovirus infection (CMV) (3 arms), sponsored by Roche. Primary endpoints: Mean Area Under the Concentration-Time Curve From 0 to 24 Hours of Valganciclovir, Number of Participants With Adverse Events Leading to Dose Interruption or Modification and 1 more. Started May 2004; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00090766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090766.